BACKGROUND
• Iron deficiency/anemia (ID/A) has been reported as a frequent comorbidity in heart failure (HF) and has been associated with impaired functional capacity, poor quality of life, and increased mortality. [1] [2] [3] • Nevertheless, little is known about the burden of ID/A in HF patients from a healthcare system / payer perspective.
• So far, healthcare utilization-in terms of hospitalisations and outpatient visits, as well as corresponding healthcare expenditures-has not been investigated for HF patients with and without ID/A, taking into account the broad spectrum of sectors in a healthcare system.
OBJECTIVES
• This descriptive study explores the demographics, NYHA (New York Heart Association) functional class, healthcare utilization, and costs for HF patients with and without ID/A in Germany.
RESULTS

Prevalence
• In total, 172,394 (4,538 per 100,000) HF patients were identified in the HRI research database in 2013.
• Of these, 11.1% were diagnosed with ID/A and/or had a prescription for iron medication. ID alone was documented in only 0.8% of the HF patients.
Demographics and NYHA Classes
• The mean age was 79.1 years for HF patients with ID/A and 76.7 years for HF patients without ID/A.
• 58.5% of the HF patients with ID/A and 54.1% of the HF patients without ID/A were female.
• HF patients with ID/A presented more often with NYHA classes III and IV (Figure 1 ) and had higher all-cause mortality (17.8% vs 10.8%) (Figure 2 ).
Iron Treatment
• The majority of HF patients with ID/A did not receive iron treatment (56.1%). Oral iron was administered in 37.9% and intravenous iron in 6.0% of patients (Figure 3 ).
METHODS
• We conducted a retrospective claims database analysis with an age-and gender-adjusted sample from the Health Risk Institute (HRI) research database containing anonymised healthcare claims of over 4 million covered lives.
• The study period spanned from January 1, 2012 to December 31, 2014.
• HF patients were identified using International Statistical Classification Of Diseases And Related Health Problems, 10th revision, German Modification (ICD-10-GM) codes (I50.-) in the inpatient (main or secondary diagnoses) and/or outpatient setting (verified diagnoses) in 2013.
• They were stratified into HF patients without ID/A and HF patients with ID/A using ICD-10-GM codes (D50.-, D50.0, D50.8, D50.9, E61.1) or ATC codes for prescribed iron medication (B03A).
• For HF patients without ID/A, the index quarter was defined by the first HF diagnosis in 2013.
• For HF patients with ID/A, the first quarter in 2013 with either both an HF diagnosis and an iron prescription or both an HF diagnosis and an ID/A diagnosis determined the index quarter.
• Patients were described in terms of age and sex at January 1, 2013. They were stratified into NYHA functional classes using the highest NYHA functional class coded in 2013. Patients without recorded NYHA functional class were assigned to the group NYHA n/a.
• Furthermore, HF patients with ID/A were stratified into 3 subgroups: no iron treatment, oral iron treatment, and intravenous iron treatment.
• Healthcare utilization and costs were assessed in a 1-year time frame, including the index quarter and the following 3 quarters. Hospitalisations were regarded as HF-related if HF was coded as the main or secondary diagnosis. Outpatient visits were considered to be HF-related if HF was coded as a verified diagnosis in the same quarter.
• The data analysis was performed in cooperation between Xcenda GmbH and Elsevier Health Analytics.
Figure 1. Distribution of NYHA Functional Classes
Legend: HF=heart failure; NYHA=New York Heart Association; ID/A=iron deficiency/anemia; n/a=not available.
Figure 2. Mortality Stratified by NYHA Functional Classes
Legend: HF=heart failure; NYHA=New York Heart Association; ID/A=iron deficiency/anemia; n/a=not available. 
CONCLUSIONS
• ID/A is a cost driver in patients with HF. HF patients with ID/A have higher all-cause mortality and cause higher healthcare utilization and costs.
• Compared to previous findings 1, 4 , this claims database analysis suggests that ID/A is underdiagnosed in the German setting. Especially ID alone is almost non-existent according to our findings.
• The study revealed that HF patients with ID/A are, on average, older and sicker in terms of NYHA classification, with a higher proportion of women than HF patients without ID/A. These findings are in line with evidence obtained in other observational studies.
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• In addition, the data suggests that ID/A in HF patients is undertreated and that intravenous iron is a rarely chosen treatment option in the German setting, despite clinical guidelines suggesting this treatment.
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• Recent studies have shown that treatment with intravenous iron can improve the functional capacity, symptoms, and quality of life in patients with HF and ID. 6, 7 • Therefore, future research should focus on the impact of intravenous iron treatment on healthcare utilization and costs in HF patients with ID/A. Healthcare Utilization
• 50.4% of the HF patients with ID/A presented with an HF-related hospitalisation compared to 31.1% of the HF patients without ID/A. The average length of stay per hospitalisation was 15.4 days and 13.6 days, respectively.
• HF patients with ID/A had, on average, 32.0 HF-related outpatient visits compared to 19.3 in HF patients without ID/A.
Healthcare Costs
• The mean overall healthcare costs amounted to €14,999 in HF patients with ID/A and €6,916 in HF patients without ID/A. The cost driver among HF patients with ID/A was inpatient care, with mean costs of €8,463 ( Table 1) .
LIMITATIONS
• In general, claims data analyses are subject to limitations, as they are primarily collected for accounting purposes, and therefore clinical parameters are not covered. 
